$REGN

Regeneron Pharmaceuticals

$REGN

Regeneron Pharmaceuticals

Past 12mo:19mentions2voices

All voices7 calls past 12moshow all

Loading price chart…

About this stock

Over the past 12 months, $REGN has generated 19 mentions from two distinct FinTwit voices: @adamfeuerstein and @jacobplieth, each contributing 11 mentions. Discussion of Regeneron Pharmaceuticals began on July 31, 2025, and continued through May 18, 2026, with activity concentrated in the biotech sector commentary. The most recent mentions from May 2026 reflect critical assessment of the company's recent developments and clinical outcomes.

AI-generated from tracked posts · updated Jul 3, 2026

Frequently asked

Related stocks

$ALLOAllogene Therapeutics

$ARVNArvinas

$ATRAAtara Biotherapeutics

$BNTXBioNTech SE

Recent calls

7 calls

@adamfeuersteinApr 23, 2026 · 4:59 PM

$REGN wins FDA approval for its gene therapy to treat a very rare genetic form of hearing loss. The company is giving away the therapy for free. OTOF-related hearing loss affects approx. 50 newborns per year, so really rare, but... are there any concerns from other gene therapy makers about a precedent being set whereby an otherwise expensive treatment is given away for free?

Open on X

@adamfeuersteinDec 19, 2025 · 12:25 PM

Important new FDA reporting from @LizzyLaw_ @statnews FDA voucher program has become vehicle for political interference in drug review decisions, staffers say A new program intended to fast-track drug reviews at the Food and Drug Administration is quickly becoming a way for the White House and top political officials at the agency to exert control over which medicines make their way fastest to patients in the United States. -- Makary clears all voucher selections with the White House, inserting politics into FDA decision making. -- The White House is using the vouchers as bargaining chips in drug-pricing negotiations. -- Some vouchers awarded despite concerns of FDA staff, including $REGN gene therapy for type of deafness. -- Focus on voucher products means FDA staff has less time/resources to spend on reviews of other products. -- Vinay Prasad exerting greater control and inflluence over voucher reviews. -- $LLY demanded faster review of oral obesity drug. FDA complied, raising similar "FDA captured by industry" concerns that arose with Biogen and Aduhelm. Read the full story. Link below.

Open on X

@adamfeuersteinOct 13, 2025 · 2:37 PM

FDA declares Novo Nordisk $NVO (Catalent) plant, key to drug manufacturing for some biotechs, out of compliance. Impacting $SRRK and $REGN today. https://t.co/LLlei1xM7X via @elaineywchen

Open on X

@jacobpliethSep 24, 2025 · 8:50 AM

CRLs for $REGN Eylea & odronextamab, & $SRRK apitegromab, so it must be time for a party! https://t.co/S78cFYGFkh

Open on X

@adamfeuersteinAug 1, 2025 · 10:43 AM

$REGN regulatory update: Expects Eylea HD pre-filled syringe and RVO approval delays (August PDUFAs) due to FDA general site inspection issues at Catalent's Indiana manufacturing plant. That facility recently acquired by $NVO Odronextamab rejected (PDUFA was July 30) also due to Catalent facility.

Open on X

@jacobpliethAug 1, 2025 · 10:34 AM

$REGN third CRL for odronextamab! https://t.co/1CspjVXeCI

Open on X

@jacobpliethJul 2, 2025 · 3:45 PM

@BiotechObserver Patient deaths, manufacturing cockups, 2 CRLs, one indication dropped. Right... $REGN

Open on X

Who mentions $REGN most on Surfaced?

@adamfeuerstein (Adam Feuerstein ✡️) mentions $REGN most — 11 mentions in the past 12 months.

When was $REGN first mentioned on Surfaced?

The earliest tracked mention of $REGN in the Surfaced archive was on Jul 31, 2025.

How many voices track $REGN?

2 FinTwit voices have mentioned $REGN 19 times in the past 12 months.

What kind of voices mention $REGN most?

$REGN is mentioned most by Biotech voices on Surfaced.